CHEMOPREVENTIVE ROLE OF COMBINATION OF ETORICOXIB AND ATORVASTATIN ON COLON CANCER INDUCED BY 1, 2-DIMETHYL HYDRAZINE ON RATS
Keywords:
Colon cancer, Chemoprevention, 1, 2-dimethylhydrazine, Etoricoxib, AtorvastatinAbstract
Objective: To investigate and compare the efficacy of atorvastatin, etoricoxib and combination of both drugs against colon carcinogenesis in male wistar rats.
Methods: Male wistar rats were divided into five groups. Group-1 served as normal control. Group-2 subcutaneously received 1,2-dimethylhydrazine (DMH) (20 mg/kg body weight(b. w.)) and served as DMH control. Groups-3, 4 and 5 were treated with DMH once in a week for 17 weeks. One week before the administration of DMH, group-3 and group-4 received etoricoxib (0.64 mg/kg per oral (p. o)), atorvastatin (2.5 mg/kg subcutaneously (s. c)) respectively and group-5 received both drugs and lasted until the end of the experiment. The effect of drugs on body weight gain, food and water intake, haematological parameter and histopathological view of the colon was observed in the entire group of animals.
Results: The experimental evidences showed that significant effect of the combined dose of etoricoxib and atorvastatin against DMH induced colon cancer by increasing the level of antioxidant enzymes. The combination was found to decrease the occurrence of multiple plaque lesions which may become the basis for its better chemo preventive action against the progression of colon carcinogenesis as compared to individual drugs. The histopathological study demonstrated that the combination treatment showed more positive effect then individual drug in prevention of colon carcinogenesis by reducing the inflammation, hyperplastic and dysplastic changes in colon crypt cells.
Conclusion: This study was concluded that the combination of atorvastatin and etori coxib may be potential chemo preventive agents against DMH-induced colon cancer and showed prominent positive effects as compared to individual drugs.
Â
Downloads
References
American Cancer Society. Colorectal Cancer Facts & fig. 2011-2013. Atlanta, Ga: American Cancer Society; 2011.
American Joint Committee on Cancer. Colon and rectum. In: AJCC Cancer Staging Manual. 7th ed. New York: Springer; 2010. p. 143-64.
Aune D, Chan DS, Lau R, Vieira R, Greenwood DC, Kampman E, et al. Dietary fibre, whole grains, and risk of colorectal cancer: systematic review and dose-response meta analysis of prospective studies. Br Med J 2011;343:6617.
Cole BF, Baron JA, Sandler RS. Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. J Am Med Assoc 2007;297:2351-9.
Fitz Gerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. Engl J Med 2001;345:433-42.
Compton C, Hawk E, Grochow. Colon cancer. Clinical Oncology. 4th ed. Philadelphia, Pa: Elsevier; 2008. p. 1477-534.
Stancu C, Sima A. Statins: mechanism of action and effects. J Cell Mol Med 2001;5:378-87.
Faivre J, Bonithon-Kopp C. Chemoprevention of colorectal cancer. Recent Results Cancer Res 1999;151:122-33.
Bresalier RS. Calcium, chemoprevention, and cancer: a small step forwards (a long way to go). Gastroenterology 1999;116:1261-3.
Helena brentani. Microarray as a tool for cancer diagnosis and prognosis. Braz J Pharm 2005;41:31.
Fearon E, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
He TC, Sparks AB, Rago C. Identification of c-MYC as a target of the APC pathway. Science 1998;281:1509-12.
Kinzler KW, Nilbert MC, Su LK. Identification of FAP locus genes from chromosome 5q21. Science 1991;253:661-5.
Kopnin B. Genetic events responsible for colorectal tumorigenesis: achievements and challenges. Tumor 1993;79:235-43.